Tingting Tan, M.D., Ph.D.
- Breast Cancer
- Medical Oncology
- Thoracic Oncology
- Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Tingting Tan, M.D., Ph.D., is internationally renowned for studying the molecular signaling pathways in tumor development and the mechanisms of chemotherapy resistance. She is board certified in medical oncology, hematology, and internal medicine.
Dr. Tan's research has been published in multiple medical and scientific journals, including Oncologists, Cancer Cell and Genes and Development. A graduate of the Beijing Medical University, Dr. Tan holds an M.D. from Peking University Health Science Center and a Ph.D. from Rutgers University. Dr. Tan's training includes fellowships at the University of California San Francisco Cancer Research Institute and the Fox Chase Cancer Center at Temple University.
Dr. Tan is dedicated to providing exceptional and compassionate care to her patients, whom she regards as family members.
"City of Hope brings every component of cancer care to each individual patient," she said. "It's not just the science behind it; it's also the compassion."
Dr. Tan is the recipient of numerous awards, including the Beijing Medical University Outstanding Graduate Award, The Lou Lehman Hospitalist Award for Excellence and the Cancer Center of New Jersey's Gallo Award for Outstanding Cancer Research.
Location
Newport Beach
Newport Beach, CA 92660
Education & Experience
2015, Board Certified in Hematology
2014, Board Certified in Medical Oncology
2010, Board Certified in Internal Medicine
2001-2006, Ph.D., Rutgers University, State University of New Jersey, NJ
1998-2001, M.D., Internal Medicine, Peking University Health Science Center, China
1993-1998, M.D., Beijing Medical University, China
2011-2014, Fellowship, Hematology and Medical Oncology Fellowship Program, Fox Chase Cancer Center-Temple University, PA
2006-2007, Postdoctoral Fellow, UCSF Cancer Research Institute, San Francisco, CA
2007-2010, Residency, Internal Medicine Residency Program, Kaiser Foundation Hospital, San Francisco, CA
2024 - Present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Newport Beach
2020 - 2024, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Newport Beach and Duarte, CA
2014-2020, Associate Physician, Los Angeles Hematology/Oncology Medical Group, Los Angeles Cancer Network, Los Angeles, CA
2010-2011, Hospitalist, Cogent Healthcare St. John’s Regional Medical Center, Oxnard, CA
Awards & Memberships
Awards
2005, Gallo Award for Outstanding Cancer Research, The Cancer Institute of New Jersey
2010, The Lou Lehman Hospitalist Award for Excellence in Hospital Medicine, Kaiser San Francisco Department of Hospital Medicine
1998, Outstanding Graduate, Beijing Medical University
1998, Jian-Hao Chinese National Scholarship, Jian-Hao National Education Foundation
Memberships
2012, American Society of Clinical Oncology
Publications
- Plimack ER, Tan T, Wong Y, von Mehren M, Maizzia L, Roethke SK, Litwin S, LI, T, Hudes GR, Hass NB. A phase I study of Temsirolimus and Bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The Oncologist April 2014 vol. 19 no. 4 354-355
- Andreu P, Magnus Johansson M, Affara N, Pucci F, Tan T, Junankar S, Korets, L, Lam, J, Tawfik D. DeNardo DG, Naldini L, de Visser K, De Palma M, Coussens LM. FcRy Activation Regulates Inflammation-Associated Squamous Carcinogenesis. Cancer Cell 2010 Feb. 17; 17(2):111-2
- Karp C, Tan T, Mathew R, Nelson D. Mukherjee C, Degenhardt K, Karantza-Wadsworth V, White E. Role of the polarity determinant Crumbs in suppressing mammalian epithelial tumor progression. Cancer Research 2008 Jun1;68(11):4105-05
- Tan T, White E. Therapeutic targeting of death pathways in cancer. In: Programmed cell death in cancer progression and therapy. Series Editors: Khosravi-Far R, White E, The Netherlands: Springer, 2008 615:81-105
- Johansson M, Tan T, De Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem, 2007 July 1, 1001(4):918-26
- Tan T, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol, 2007 Apr; 19(2):209-16
- Tan T, Degenhardt K., Nelson DA, Beaudoin B, Nieves-Neria W, Bouillet P, Adams JM, White E. Key Roles of BIM-driven Apoptosis in Epithelial Tumors and Rational Chemotherapy. Cancer Cell, 2005 Mar: 7:227-238
- Nelson DA, Tan T (co-first author), Rabson A, Anderson D. Degenhardt K, White E. Hypoxia and Defective Apoptosis Drive Genomic Instability and Tumorigenesis. Genes and Development 2004. Sep: 18:2095-2107
- Guo LJ, Tan T and Mao JM, Zhonghua Yi Xue Za Zhi. Clinical manifestation and prognosis of the myocardial bridge (Chinese). 2003 Apr 83:553-555